Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.45 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12473845 | 0.90 | POLB (0.42) | KDM4EALDH1A1HSD17B10HPGDMEN1 | |
| SCHEMBL570442 | 0.85 | PDE10A (0.40) | KDM4EALDH1A1HSD17B10TSHRMAPT | |
| SCHEMBL570115 | 0.83 | KDM4E (0.38) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL15064484 | 0.81 | PDE10A (0.43) | KDM4EALDH1A1HPGDHTTTSHR | |
| SCHEMBL15064353 | 0.80 | KDM4E (0.37) | KDM4EALDH1A1HSD17B10HTTTSHR | |
| SCHEMBL10285695 | 0.77 | MEN1 (0.40) | KDM4ETSHRMAPTMEN1KMT2A | |
| SCHEMBL570302 | 0.77 | ALDH1A1 (0.40) | KDM4EALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL570861 | 0.76 | KDM4E (0.36) | KDM4EMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL12045528 | 0.76 | ALDH1A1 (0.50) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL570749 | 0.74 | MEN1 (0.36) | KDM4EHSD17B10TSHRMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601192-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE10A, PDE3A, PDE2A | KDM4E 1619/4885ALDH1A1 270/4885HSD17B10 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.